20S Proteasome Activator Medicines
preclinicaldrug program · high · Thu Nov 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop small molecules that directly activate 20S proteasomes to restore proteasome function, clear disease-causing proteins, rebalance cellular homeostasis, and advance toward first-in-human Phase 1 testing, initially in neurodegenerative diseases including Parkinson's disease.
Small-molecule direct activation of the 20S proteasome to boost cellular protein quality-control machinery.
Awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to advance a new class of proteasome activator medicines toward a first-in-human Phase 1 study.